TruLab Peptides
Mass-spec-verified research-grade peptides - the catalog the peptide community actually trusts.
A research-peptide catalog with the rarest combination in the category - third-party mass-spec verification published per lot, public CoAs, and an actually navigable storefront.
The research-peptide market is dominated by no-name vendors with sketchy provenance, lots of marketing claims, and very little verified analytical data. TruLab is on the small list of brands that publishes per-lot mass-spec verification and certificate-of-analysis documents alongside every SKU.
The catalog covers the standard research-peptide names that come up in longevity discussions: BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295, GHK-Cu, semaglutide research-only, tirzepatide research-only, and the broader GH-secretagogue family. Pricing is mid-tier - not the cheapest, not the most expensive - and the storefront is actually navigable, which is rare in this category.
Important compliance note: peptides sold for research use only are not for human consumption, and no claims about therapeutic use are made. This is a research catalog, not a clinical-grade supplement.
Researchers, lab managers, and longevity-curious buyers who want third-party-verified peptide provenance for research applications.
You want clinical-grade peptides for human use - those require a licensed practitioner via a compounding pharmacy (Marek Health, Lifeforce, etc.), not a research catalog.
Pros
- Third-party mass-spec verification + certificate-of-analysis published per lot
- Catalog covers the standard research-peptide names: BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295, GHK-Cu
- GLP-1 research peptides (semaglutide, tirzepatide) included
- Mid-tier pricing - not the cheapest, not the most expensive
- Domestic US shipping (no customs delays)
- Storefront is navigable - rare in this segment
Cons
- Research-use designation only - NOT for human consumption per labeling
- Compliance burden on the buyer to use only in research applications
- Newer brand (2023) - long-term operational track record limited
- Peptide market itself is regulatorily fluid; FDA enforcement actions on compounded peptides have increased in 2024-2026
Specifications
Most often compared with
Where this fits
TruLab Peptides Research Peptides Catalog cross-shops across several editorial surfaces - the full brand catalog, the buyer-intent tags this item carries, the price band it qualifies for, and any execution playbook that uses it.
TruLab Peptides Research Peptides Catalog - buyer FAQ
What does "research use only" actually mean?
Research peptides are sold for laboratory research applications, explicitly not for human consumption. The FDA regulates research-use-only products differently than supplements or drugs - no human therapeutic claims, no quality oversight for consumption. The category exists because peptides like BPC-157 and TB-500 haven't been FDA-approved as therapeutics. TruLab's positioning + per-lot CoAs are the safest end of a gray market.
TruLab vs gray-market peptide vendors?
TruLab publishes third-party mass-spectrometry verification + per-lot Certificates of Analysis. Most gray-market peptide vendors don't. The premium over commodity research peptides ($50-100 vs $30-60) is the verification + provenance + compliance posture. For buyers doing peptide research, TruLab is the conservative-correct pick.
Will FDA crack down on this category?
Already started. Late-2024 FDA actions targeted compounded peptides + research-grade vendors making therapeutic claims. As of 2026 the enforcement landscape evolves quarterly. Brands that maintain strict research-use positioning and don't make therapeutic claims (like TruLab) are lower-risk; brands that wink at therapeutic use are higher-risk.